From: Federal Government(Federal)
Jun 09, 2017 11:26 am
Sandia National Laboratories (SNL) has developed and patented technologies related to microneedles for in-vivo monitoring of health and performance. These sensors can monitor physiological analytes such as lactate and electrolyte levels.. The device is painless, using tiny needles that don't traumatize nerves but can still sample blood or interstitial fluid and can be configured as a wearable or a portable diagnostic device. SNL has performed proof of principle trials in human subjects and is looking for partnerships to further develop hardware and electronics to integrate components into a completely autonomous device as well as expand clinical trials for creation of necessary algorithms capable of assessing medical diagnosis.
Available Intellectual Property:
US Application 14/538,096 (SD 12816 and 13356) INTEGRATED FLUIDIC CHIP FOR TRANSDERMAL SENSING OF PHYSIOLOGICAL MARKERS
US Application 14/746,301 (SD 13158) "DIAGNOSTIC/DRUG DELIVERY "SENSE-RESPOND" DEVICES, SYSTEMS, AND USES THEREOF"
US Application 15/078,870 (SD 13361) "In-Vivo Extraction of interstitial Fluid Using Hollow Microneedles"
PCT/US2016/024747 (SD 13361) "In-Vivo Extraction of interstitial Fluid Using Hollow Microneedles"
US Application 15/237,193 (SD 13334) "Electromolding for creation of biocompatible hollow microneedle arrays"
- Capable of performing in-vivo medical diagnostics
- Detects a wide range of biological agents: lactate, electrolytes, and proteins
- Point of Care (POC) diagnosis and drug delivery
- Wearable or point of care use
SNL is seeking partners to further develop and commercialize microneedle array sensors. Cooperative Research and Development Agreements (CRADAs) and Licensing Agreements are available.
Sandia invites interested parties to provide a detailed description of relevant background, experience, expertise, and capabilities that could be brought into a collaborative partnership with Sandia. Specific requirements are as follows:
1) Companies that are able to enter into a CRADA agreement with Sandia National Laboratories, which requires in-kind contribution in the form of laboratory staff and instrumentation
2) Companies capable of providing a minimum of $600K funds-in
3) Companies capable of substantial manufacturing in the U.S.
4) Demonstrated experience in bringing products to market
1) Demonstrated experience, expertise, and capabilities in the design, development and manufacturing of medical equipment
2) Demonstrated successful partnering and teaming relationships with R&D organizations
In addition to evaluating the provided information as outlined above, Sandia will evaluate all responses and select prospective parties with which to engage in further discussions based on the following criteria, pursuant to Sandia's technology transfer mission:
1) How will the respondent deploy the technology for the benefit of the U.S. public good?
2) How will the respondent's deployment of the technology benefit U.S. economic competitiveness?
Sandia National Laboratories is a multimission laboratory managed and operated by National Technology & Engineering Solutions of Sandia, LLC., a wholly owned subsidiary of Honeywell International, Inc., for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-NA0003525.Keywords:
Microneedle, Sensor, electrochemistry, point of care, health monitoring